Condition: Gynecologic Cancer · Skin Cancer · Head and Neck Cancer · Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers. Patients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease. The primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients with rare oligometastatic cancers.
This description comes directly from the study's public registry record.
EORTC HQ · +32 2 7744 1611 · eortc@eortc.org
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
| Gasthuiszusters Antwerpen - Sint-Augustinus | Wilrijk, Belgium | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Gustave Roussy | Villejuif, France | Recruiting |
| Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center | Hamburg, Martinistrasse 52, Germany | Recruiting |
| Istituto Europeo di Oncologia | Milan, Italy | Recruiting |
| Medical University Of Gdansk | Gdansk, Mariana Smoluchowskiego 17, Poland | Recruiting |
| Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology | Warsaw, Poland | Recruiting |
| Inselspital | Bern, Switzerland | Recruiting |
| UniversitaetsSpital Zurich | Zurich, Switzerland | Recruiting |
| University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical Centre | Birmingham, United Kingdom | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04498767